Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients. 2019

Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
Nephrology and Dialysis Unit, "Maggiore della Carità" University Hospital, Corso Mazzini 18, 28100, Novara, Italy. andreanademauri@libero.it.

BACKGROUND Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a serine lipase that enhances the instability of the atherosclerotic plaques. While in the general and cardiac population Lp-PLA2 is recognized as an important determinant of cardiovascular (CV) accidents, no data are available for the renal population. The aim of this study was to evaluate the relationship between Lp-PLA2 and acute CV events in hemodialyzed patients. METHODS We enrolled 102 dialyzed patients, 63% male, age 71 years (59-78), 35% with diabetes, 54% hypertension, 40% coronary artery disease and 31% peripheral vascular disease. They were investigated for Lp-PLA2 (cut-off < 194 nmol/min/ml), lipoprotein profile and the occurrence of acute CV events and death in the subsequent 3 years of follow-up. RESULTS The median (interquartile ranges) levels of Lp-PLA2, total-, HDL-, LDL-cholesterol and ApoB/ApoA lipoprotein ratio were 184.5 (156.5-214.5) nmol/min/ml, 158 (127-191) mg/dl, 41 (33-51) mg/dl, 79 (63-102) mg/dl and 0.72 (0.58-0.89), respectively. In 42% of patients, Lp-PLA2 was > 194 nmol/min/ml and total- and LDL-cholesterol were higher, as well as CV morbidity and mortality. During follow-up, 51% of patients developed at least one CV event; the median survival time was 36 months, with a total and CV mortality of 42 and 29%, respectively. At multivariate Cox regression, Lp-PLA2 > 194 nmol/min/ml (HR = 2.98, p = 0.005), age (HR = 1.03, p = 0.029), diabetes (HR = 2.86, p = 0.002) and hypertension (HR = 2.93, p = 0.002) were independently associated with time to CV events. CONCLUSIONS Lp-PLA2 activity is elevated among dialyzed patients and is an independent risk factor for acute CV events in a mean follow-up of 3 years.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
January 2012, PloS one,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
April 2008, Transplantation,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
January 2015, Journal of cardiovascular medicine (Hagerstown, Md.),
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
September 2006, Current atherosclerosis reports,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
January 2017, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
September 2006, Clinics in laboratory medicine,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
February 2011, Harefuah,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
January 2024, Lipids in health and disease,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
March 2022, Biomedical and environmental sciences : BES,
Andreana De Mauri, and Matteo Vidali, and Doriana Chiarinotti, and Giorgio Bellomo, and Roberta Rolla
March 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!